{
  "docId": "019dd923-5f69-752d-a9b8-7335d4e4bbbd",
  "docSlug": "UazyKuUCi7yVVPL3wJds",
  "documentTitle": "See the pitch deck that Compass Pathways used to raise $80 million and fuel its rise into one of the world's biggest psychedelics companies",
  "authorId": "Pitchdecks",
  "authorName": "Compass Pathways",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.333,
  "pageNumber": 8,
  "pageCount": 28,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "why_now",
  "function": "argue_timing",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "The slide uses a list format to present key value drivers for the company's core asset.",
  "elementsJson": [
    "action_title",
    "bullet_list",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5f69-752d-a9b8-7335d4e4bbbd/8",
  "deckHref": "/decks/019dd923-5f69-752d-a9b8-7335d4e4bbbd",
  "deckJsonHref": "/decks/019dd923-5f69-752d-a9b8-7335d4e4bbbd.json",
  "deckAnchorHref": "/decks/019dd923-5f69-752d-a9b8-7335d4e4bbbd#slide-8",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Preliminary clinical evidence indicates the drug may demonstrate substantial improvement over existing therapies to treat a serious or life threatening disease or condition",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-a290-75b0-a217-07989385454f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.11,
        "w": 0.88,
        "x": 0.06,
        "y": 0.19
      },
      "kind": "list",
      "text": "Value Proposition: Attractive therapeutic, patient, and economic benefit profile, with over 70% of patients rank psilocybin therapy among top 5 most meaningful experiences of their lives",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "10ff5382-49cd-4e96-a063-cbab74827aea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.11,
        "w": 0.88,
        "x": 0.06,
        "y": 0.69
      },
      "kind": "list",
      "text": "Strong IP position: Never registered as new chemical entity (NCE) and strong protection from four independent sets of patent claims filed in UK/PCT*/US in Oct2018; market protection from generics for 8-11 years in EU, 5-7.5 years in US",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4695c485-b2fb-4a22-8bcb-1e96643005ce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.88,
        "x": 0.06,
        "y": 0.47
      },
      "kind": "list",
      "text": "Promising clinical evidence: Strong signals from Phase I/IIa studies by top research institutions in EU and US",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b91aefe-453a-4f98-9f3b-9ca6e17fb752",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.11,
        "w": 0.88,
        "x": 0.06,
        "y": 0.33
      },
      "kind": "list",
      "text": "FDA ‘Breakthrough Therapy Designation’ received in Oct2018: “Preliminary clinical evidence indicates the drug may demonstrate substantial improvement over existing therapies to treat a serious or life threatening disease or condition”",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dd33e007-b7e2-4c7f-bcca-f02375e79d13",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.88,
        "x": 0.06,
        "y": 0.58
      },
      "kind": "list",
      "text": "Safe substance: Low harm and dependence potential and no significant adverse events in studies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dfdb53ab-6819-4c23-bdbd-9582245251ab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "patient experience: 70%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-a290-75b0-a217-0b8baeb85cd1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.15,
        "x": 0.06,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "Source: 1. Griffiths et al (2016)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ced6ab8a-c3bf-49a3-9d14-2f27b23dfa50",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.25,
        "x": 0.06,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "* PCT = Patent Cooperation Treaty",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f69d08b8-babd-4742-a33e-5c6663ef08ba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.11,
        "w": 0.88,
        "x": 0.06,
        "y": 0.03
      },
      "kind": "title",
      "text": "Breakthrough Therapy: Psilocybin presents significant scientific and commercial opportunity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a2b6bebb-78e9-4aa8-9a38-cc6e19d6114e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 9,
      "from": 8,
      "beatId": "554d3b9d-f4da-4b84-9feb-45a0d75afc78",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "Slides 8 and 9 agitate the problem by highlighting the breakthrough therapy designation for psilocybin and its potential benefits.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 8,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "2c026b6f-bde1-4704-bc90-2f6332879c93",
      "evidence": "The breakthrough therapy designation and potential for accelerated approval are highlighted.",
      "position": 1,
      "objective": "Explain why now is the time for psilocybin therapy",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 0.7,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}